Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients

Abstract

Objective:

To compare asthma-related resource utilization, adherence and costs among adults prescribed asthma controller regimens.     

Predictors of asthma control in everyday clinical practice in Switzerland

Abstract

Objective:

To identify predictors of improved asthma control under conditions of everyday practice in Switzerland.     

Smoking influences response to inhaled corticosteroids in patients with asthma: a meta-analysis

Abstract

Objective:

To determine the effects of smoking on efficacy of inhaled corticosteroids in asthmatics.     

Efficacy,safety, and tolerability of mometasone furoate in adult Japanese patients with mild asthma: open-label clinical trial findings

Abstract

Objective:

To evaluate the clinical efficacy and safety of mometasone furoate administered via a dry powder inhaler (MF-DPI) in Japanese patients with intermittent or mild persistent asthma who were not previously receiving inhaled corticosteroids.     

Controlled and uncontrolled allergic asthma in routine respiratory specialist care – a clinical–epidemiological study in Germany

Abstract

Background:

Studies in the last decade showed high rates of poorly treated and poorly controlled asthma in the community. Extending these findings we describe the more recent situation in specialist respiratory care as the most frequent source of treatment provision using comprehensive clinical and patient assessments and exploring predictors for poor control.     

Patient and Physician Satisfaction with Rofecoxib in Osteoarthritis: Results of the EVA (Experience with VIOXX in Arthritis) Survey. Current Medical Research and Opinion, 17(2): 81-8, 2001

Abstract

Background:

Several studies have demonstrated the beneficial effects of omalizumab in asthma patients. Here we describe the drug’s tolerance and oral corticosteroid sparing capacity in a long-term observational study.     

Effect of increased body mass index on asthma risk,impairment and response to asthma controller therapy in African Americans

Abstract

Objective:

To explore whether obesity alters the risk, impairment and response to treatment in African Americans with asthma.     

The ARGA study with Italian general practitioners: prescriptions for allergic rhinitis and adherence to ARIA guidelines

Abstract

Background:

General practitioners (GPs) are the healthcare professionals to whom patients with rhinitis firstly refer for their symptoms.     

Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma

Abstract

Objective:

To investigate the clinical benefits of ‘add-on’ therapy with GSK2190915 in combination with the inhaled corticosteroid (ICS) fluticasone propionate (FP) and the ICS/long-acting beta 2 agonist (LABA) combination FP/salmeterol in asthmatic subjects.     

Leukotriene D4 bronchial provocation test: methodology and diagnostic value

Abstract

Background:

Although leukotriene D4 (LTD4) is a potent bronchoconstrictor, little is known about airway responsiveness to LTD4 in asthmatics with different inflammation phenotypes.     

Development of the Asthma Treatment Satisfaction Measure

Abstract

Objective:

Study aims were to develop and assess the measurement properties of a four-part treatment satisfaction measure for patients with asthma. The Asthma Treatment Satisfaction Measure (ATSM) incorporates specific attributes representing patient expectations, treatment preferences, self-reported treatment outcomes, and overall treatment satisfaction. This paper describes patients’ ability to detect change in their satisfaction with asthma therapies using the ATSM.     

Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors

Abstract

Objectives:

To examine the real-life effectiveness of inhaled corticosteroids (ICS) versus leukotriene receptor antagonists (LTRA) monotherapy in children with mild or moderate asthma.     

Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients

Abstract

Background:

Ticagrelor is a direct-acting, reversibly binding, oral P2Y₁₂ platelet inhibitor that reduces thrombotic cardiovascular events in patients with acute coronary syndrome. Dyspnea is one of the most commonly reported adverse events associated with ticagrelor.     

Could FEV1 decline have a role in daily clinical practice for asthma monitoring?

Abstract

Objective:

The aim of this review was to understand whether FEV₁ decline measured during the follow-up of asthmatic subjects (FEV₁ variation between two different measurements at a distance of at least 5 years) may have a role in their management.     

Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial

Abstract

Objective:

To demonstrate the efficacy and safety of fluticasone propionate/formoterol fumarate (flutiform) in a pressurised metered-dose inhaler (pMDI) compared to two formulations of the fluticasone propionate component (Skyepharma fluticasone [SKP FP] or Flovent, GlaxoSmithKline [GSK FP]) in adults and adolescents with moderate-to-severe asthma.     

Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial

Abstract

Background:

The potent inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting β₂-agonist with a rapid onset of action, formoterol fumarate (formoterol), have now been combined in a single aerosol inhaler, fluticasone/formoterol (flutiform). This study investigated the efficacy and safety of fluticasone/formoterol combination therapy compared with its individual components administered concurrently via two separate inhalers.     

Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma

Abstract

Background:

Inhaled corticosteroids (ICSs) are effective controller medications that treat the chronic inflammation of asthma. The goal of asthma treatment is to improve lung function, symptoms, and the ability to perform daily activities, while decreasing the risk of exacerbations. Mometasone furoate delivered via a dry powder inhaler (MF-DPI) is indicated for once-daily maintenance treatment of asthma in patients as young as 4 years old.     

Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma

Abstract

Objective:

Omalizumab is a monoclonal antibody indicated for adults and adolescents with moderate-to-severe persistent allergic asthma whose symptoms are inadequately controlled with inhaled corticosteroids. Omalizumab has been demonstrated to improve health outcomes of asthmatic patients as compared to placebo. However, to date, the trials conducted have been relatively short (less than 1 year) and have been restricted to a limited set of patients who met the clinical study criteria. This study examined the expected effects of omalizumab over 5 years on a representative sample of all patients eligible for omalizumab in the US.     

Clinical study of the effects on asthma-related QOL and asthma management of a medical food in adult asthma patients

Abstract

Background:

Asthma can have a negative impact on quality of life although this is not well correlated with objective evaluations of pulmonary function. A medical food, EFF1009, containing the fatty acids gamma-linolenic acid (GLA) and eicosapentaenoic acid (EPA) decreases leukotriene B₄ synthesis in patients with asthma. Two previous clinical studies with EFF1009 provided preliminary evidence that the medical food improves asthma-related quality of life (ARQOL) and asthma management.